Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.

@article{Bristow2007IntraperitonealCA,
  title={Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.},
  author={Robert Evan Bristow and Antonio Santillan and Ritu Salani and Teresa P. D{\'i}az-Montes and Robert L. Giuntoli and Benjamin C Meisner and Deborah K. Armstrong and Kevin D. Frick},
  journal={Gynecologic oncology},
  year={2007},
  volume={106 3},
  pages={476-81}
}
OBJECTIVE To evaluate the cost-effectiveness of intraperitoneal cisplatin and paclitaxel chemotherapy as front-line treatment for patients with Stage III epithelial ovarian cancer following optimal primary cytoreductive surgery. METHODS Based on Gynecologic Oncology Group protocols #172 and #158, a decision analysis model was created to compare two treatment strategies for patients with optimal residual disease Stage III ovarian cancer: (1) inpatient intravenous paclitaxel (24 h) and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Can we maximize both value and quality in gynecologic cancer care? A work in progress.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting • 2014

Similar Papers

Loading similar papers…